The European Commission (EC) has approved the use and marketing in Europe of Rixathon, a biosimilar to Roche’s MabThera (rituximab). The decision follows a positive review of Rixathon by the Committee for Medicinal Products for Human Use (CHMP) last April in response to Sandoz’s marketing application.
News
News
Nucala Triggered Remission in Eosinophilic Granulomatosis with Polyangiitis, But Not All Benefit
Nucala (mepolizumab) effectively induced remission in about half of patients with eosinophilic granulomatosis with polyangiitis (EGPA) that relapsed or did not respond to treatment, according to results from a Phase 3 clinical trial (NCT02020889). The study found that Nucala reduced…
Recent Posts
- Urine protein fragments may help assess kidney inflammation in AAV
- Most AAV patients in North America affected by lung complications
- Sharing what’s on your mind can ease loneliness in life with vasculitis
- Antibody type may influence cardiovascular risk timing in AAV
- Tapeworm medication may ease ear, nose, throat symptoms in AAV